TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06594744
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The initial dosage of carvedilol is set at 6.25 mg daily. In the absence of hypotension (systolic blood pressure \&lt; 90 mmHg), bradycardia (resting heart rate \&lt; 55 beats per minute), or other adverse effects, hospitalized patients may have their dosage increased to 12.5 mg daily after 3 days, while outpatient patients may increase their dosage to 12.5 mg daily after 7 days. This dosage represents the target dose for the trial.
Study: NCT06597682
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Total 4 weeks of treatment
Study: NCT06597682
Drug: Budesonide/Formoterol
Normalized name: BUDESONIDE/FORMOTEROL
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Total 8 weeks of treatment
Study: NCT06597682
Drug: Montelukast tablets oral treatment
Normalized name: montelukast Oral Tablet
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Total 8 weeks of treatment
Study: NCT06601127
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Day 1, loading dose of Clopidogrel and loading dose of aspirin; Day 2-21, daily maintenance dose of Clopidogrel and daily maintenance dose of aspirin; D22-90: daily maintenance dose of Clopidogrel.
Study: NCT05731804
Drug: SIM0417 375 mg; Ritonavir100 mg
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SIM0417 is single dosed, and ritonavir is administered 12 hours before SIM0417 administration (-12 hours), at the time of SIM0417 administration (0 hour), 12 hours (12 hours) after SIM0417 administration, and 24 hours (24 hours) after SIM0417 administration.
Study: NCT05731804
Drug: SIM0417 750 mg; Ritonavir100 mg
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SIM0417 is single dosed, and ritonavir is administered 12 hours before SIM0417 administration (-12 hours), at the time of SIM0417 administration (0 hour), 12 hours (12 hours) after SIM0417 administration, and 24 hours (24 hours) after SIM0417 administration.
Study: NCT05510505
Drug: CD20 monoclonal antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4.2 Conditioning Regimen~4.2.1 Matched sibling donor~1. ATG arm (control group) Fludarabine 30mg/m2/d×6d（-7d \~ -2d）+ Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）~2. ATG + CD20 monoclonal antibody (test arm) Fludarabine 30mg/m2/d×6d（-7d \~ -2d） + Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）+ CD20 monoclonal antibody 375mg/m2, -1d~4.2.2 Unrelated donor and haploidentical donor~1. ATG arm (control group) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）~2. ATG + CD20 monoclonal antibody (test arm) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）+ CD20 monoclonal antibody 375mg/m2, -1d
Study: NCT05510505
Drug: ATG
Normalized name: eATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.2 Conditioning Regimen~4.2.1 Matched sibling donor~1. ATG arm (control group) Fludarabine 30mg/m2/d×6d（-7d \~ -2d）+ Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）~2. ATG + CD20 monoclonal antibody (test arm) Fludarabine 30mg/m2/d×6d（-7d \~ -2d） + Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）+ CD20 monoclonal antibody 375mg/m2, -1d~4.2.2 Unrelated donor and haploidentical donor~1. ATG arm (control group) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）~2. ATG + CD20 monoclonal antibody (test arm) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）+ CD20 monoclonal antibody 375mg/m2, -1d
Study: NCT05317806
Drug: Metformin Extended Release Oral Tablet
Normalized name: metformin Extended Release Oral Tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: daily metformin treatment vs. no treatment with metformin
Study: NCT05808972
Drug: Sodium chloride 0.9% (SC)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This trial looks specifically at the type of hydratation liquid. The patients included will receive SC. The volume, frequency of fluid administration and other severe DKA therapies, such as insulin therapy and electrolytes, are prescribed similarly. The intervention will continue for 48 hours from admission to the ICU with a blood gas control (including base excess) + Blood glucose + ionogram (Na, K, chlorine) + lactates on admission (or H0), H6, H12, H24 and H48.
Study: NCT05087615
Drug: Metoclopramide
Normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This groups only received metoclopramide 0.2 mg/kg IV Bid as antiemetic in the postoperative period.
Study: NCT05087615
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This groups only received ondansetron 8 mg IV Bid as antiemetic in the postoperative period.
Study: NCT05087615
Drug: Metoclopramide and Ondanteron
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This groups received both metoclopramide 0.2 mg IV Bid and ondansetron 8 mg IV/Bid as antiemetics in the postoperative period.
Study: NCT05087615
Drug: Granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This groups only received granisetron 2 mg IV Bid as antiemetic in the postoperative period.
Study: NCT06297408
Drug: Relma-cel
Normalized name: relma-cel
DrugBank: Relmacabtagene autoleucel (DB18979)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19-targeted Chimeric AntigenReceptor (CAR) T Cells
Study: NCT01418547
Drug: Torrent's Isosorbide Mononitrate 120 mg ER Tablets
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04954274
Drug: Cyclic peptide Fertiline
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upon retrieval, the oocyte will be decoronized and incubated prior to ICSI procedure into CSCC-M medium supplemented with the molecule.~After ICSI, the zygote will be incubated in CSCM-C medium supplemented with the peptide.
Study: NCT04994431
Drug: Tamsulosin Hydrochloride
Normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.4mg orally nightly for the two days immediately prior to surgery and the morning of surgery.
Study: NCT06357741
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Desumumab, 60mg single injection
Study: NCT04900623
Drug: Chemotherapy drug
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiation therapy are both considered standard treatments~* Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.~* Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy.
Study: NCT06597344
Drug: Gepotidacin
Normalized name: gepotidacin
DrugBank: Gepotidacin (DB12134)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepotidacin will be administered.
Study: NCT04771442
Drug: Stromal vascular fraction
Normalized name: Autologous stromal vascular fraction from adipose tissue
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT05533281
Drug: tropisetron
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tropisetron was given 30 minutes in advance, and then tramadol 1.5mg/kg was intravenously injected with a micropump at a constant speed.
Study: NCT05533281
Drug: metoclopramide
Normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One dose of metoclopramide was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
Study: NCT05533281
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of dexamethasone was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
Study: NCT06588595
Drug: Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After at least 30 days of DAPT \[with aspirin 81-mg qd and a potent P2Y12 inhibitor (prasugrel 10 mg qd or ticagrelor 90-mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients with an ABCD-GENE 10 or more will continue prasugrel 10 mg qd/ticagrelor 90 mg BID and drop aspirin; and patients with an ABCD-GENE less than10 will switch from prasugrel/ticagrelor-based DAPT to aspirin 81 mg qd plus clopidogrel 75 mg qd.
Study: NCT06628154
Drug: Losartan potassium 50mg
Normalized name: LOSARTAN POTASSIUM 50MG TAB,UD
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose losartan (50 mg, weight-adjusted), encapsulated identically to placebo
Study: NCT00002079
Drug: Butyldeoxynojirimycin
Normalized name: Butyldeoxynojirimycin
DrugBank: Miglustat (DB00419)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00002079
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05550402
Drug: Salbutamol
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Visit 1, After predosed spirometry is done, the patients will be received 4 puffs of salbutamol. 30 minutes later, if they meet the criteria of fixed airway obstruction based on ATS criteria, then they will continue to undergo serial spirometry at 1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of ipratropium and do spirometry at 4.5 and 5 hours.
Study: NCT05550402
Drug: Ipratropium Bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Visit 2, After predosed spirometry is done, the patients will be received 4 puffs of ipratropium they will continue to undergo serial spirometry at 30 minutes,1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours.
Study: NCT05550402
Drug: Salbutamol plus Ipratropium Bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm). Then, the patients requested to be administered 4 puffs of ipratropium and 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours (Salbutamol plus ipratropium arm)
Study: NCT05252117
Drug: Articaine Hydrochloride 40 MG/ML
Normalized name: articaine hydrochloride 40 MG/ML
DrugBank: Articaine (DB09009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Analysis of uterovaginal plexus block with articain for intrauterine device placement
Study: NCT05252117
Drug: Mepivacaine
Normalized name: Mepivacaine
DrugBank: Mepivacaine (DB00961)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Analysis of uterovaginal plexus block with mepivacaine for intrauterine device placement
Study: NCT05422703
Drug: Analgesic
Normalized name: Analgesic
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSAIDs like ibuprofen (600-800 mg) or declophenac sodium (50-150 mg) 3 times a day
Study: NCT05422703
Drug: Mouth wash
Normalized name: MOUTH WASH, TABLET FOR SOLUTION
DrugBank: Thymol (DB02513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: use 0.12% chlorhexidine or povidone iodine mouthwash daily
Study: NCT06024356
Drug: Thymalfasin
Normalized name: Thymalfasin
DrugBank: Thymalfasin (DB04900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymalfasin (thymosin-alpha 1) is an immunomodulating agent able to enhance the Thl immune response. It has been evaluated for its immunomodulatory activities and related therapeutic potential in several diseases.
Study: NCT05914714
Drug: Ruxolitinib 5 MG BID Oral Tablet
Normalized name: ruxolitinib 5 MG
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ruxolitinib 5mgBID will be administrated at the beginning of the conditioning regimen until 3 months post-transplantation.
Study: NCT05830747
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative drug administration before third molar surgery
Study: NCT00002416
Drug: Emtricitabine
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002416
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04743297
Drug: Prostaglandin E2 (Propess)
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Propess - The vaginal insert is removed 24 h after the application. It is only to be removed earlier in case of the onset of active labour or at the occurrence of hyperstimulation.
Study: NCT04743297
Drug: Prostaglandin E2 (Prostin)
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostin - 3 mg vaginal tablet is placed in the posterior vaginal fornix. Dose can be repeated every 8 hours till onset of active labour or the occurrence of hyper-stimulation.
Study: NCT06348602
Drug: Cyclosporine ophthalmic solution 0.1%
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic prophylaxis begins once engraftment is documented, with a dose of 1 drop in each eye every 12 hours, continued for a duration of 12 continuous months
Study: NCT06348602
Drug: Tacrolimus ophthalmic ointment 0.03%
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ophthalmic prophylaxis begins once engraftment is documented, with a dose of approximately 1 cm or the necessary amount to cover the lower fornix, every 12 hours, continued for a duration of 12 continuous months
Study: NCT05838105
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 125 mcg once at the day mentioned
Study: NCT05838105
Drug: hCG
Normalized name: HCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose as mentioned
Study: NCT05838105
Drug: Progesterone 100Mg Vag Tab
Normalized name: PROGESTERONE 100MG VAG TAB
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dose as mentioned
Study: NCT04660643
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03172455
Drug: Glassia
Normalized name: Glassia
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application 90 mg/kg loading dose day 1, 30 mg/kg every other day (day 3 - day 15)
Study: NCT06588595
Drug: Aspirin plus clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After at least 30 days of DAPT \[with aspirin 81 mg qd and a potent P2Y12 inhibitor (prasugrel 10 mg qd or ticagrelor 90 mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will switch from prasugrel/ticagrelor-based DAPT to aspirin 81 mg qd plus clopidogrel 75 mg qd, irrespective of ABCD-GENE score.
Study: NCT05553496
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Group (1) RTX in Refractory Nephrotic syndrome patients on conventional treatment (20 patients)
Study: NCT05553496
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group (2) Refractory Nephrotic Syndrome patients on Conventional therapy (20 patients)
Study: NCT04981457
Drug: Misoprostol and iso sorbide mononitrates
Normalized name: naproxen and misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: drug
Study: NCT06602739
Drug: REGN5713
Normalized name: Immunoglobulin G4 [224-proline], anti-(Betula alleghaniensis allergen Bet v 1) (human monoclonal REGN5713 γ4-chain), disulfide with human monoclonal REGN5713 κ-chain, dimer
DrugBank: Bremzalerbart (DB19417)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered per protocol
Study: NCT04945096
Drug: decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine (20mg/m2 intravenously from day -10 to day -8 of conditional regimen)
Study: NCT04945096
Drug: Acetylcysteine
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcysteine: 1.2g twice a day, oral administration, from day -10 to day 365 after HSCT.
Study: NCT04945096
Drug: Semustine
Normalized name: Semustine
DrugBank: Semustine (DB13647)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semustine: 250 mg/m2/day on day -9.
Study: NCT04945096
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine: 2 g/m2 every 12 hours on day -8.
Study: NCT04945096
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan: 3.2mg/kg/day on day -7 to -5.
Study: NCT04945096
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A: 3mg/kg/d from day -8.
Study: NCT04945096
Drug: Anti-thymocyte globulin
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-thymocyte globulin (2mg/kg/d on day -5 to day -2) will be added for transplants with unrelated donor or HLA mismatched donor.
Study: NCT04945096
Drug: Mycophenolate
Normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mycophenolate (500mg, oral, twice a day from day -8) will be added for transplants with unrelated donor or HLA mismatched donor.
Study: NCT04589364
Drug: Injection botulinum toxin A ( Dysport 100 unit or Neuronox 33.33 unit)
Normalized name: botulinum toxin type A Injection
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: injection of toxin on facial muscle
Study: NCT06601465
Drug: Vericiguat
Normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet - 2.5 mg, 5 mg, 10 mg
Study: NCT06589765
Drug: HRS-7535 tablet
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-7535 tablet
Study: NCT06589765
Drug: dapagliflozin tablet
Normalized name: Dapagliflozin Tablets
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: dapagliflozin tablet
Study: NCT06588478
Drug: Pirtobrutinib
Normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Orally.
Study: NCT00651183
Drug: Pramipexole immediate release
Normalized name: pramipexole Extended Release Oral Tablet
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05863845
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100mg day -10, 200mg day -9, 400mg day -8, 800mg day -7 to -1, Given PO
Study: NCT05863845
Drug: Carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300mg/m2 day -7, Given IV
Study: NCT05863845
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100mg/m2/d, day -6 to day -3, Given IV
Study: NCT05863845
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200mg/m2/d, day -6 to day -3, Given IV
Study: NCT05863845
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 140mg/m2, day -2, Given IV
Study: NCT06597396
Drug: Abrocitinib
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50 mg tablets
Study: NCT06108362
Drug: Terlipressin
Normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The medication is dispensed by the nursing staff before surgery and given to the anesthesiologist before the procedure begins
Study: NCT06587217
Drug: Carbidopa 25 mg
Normalized name: carbidopa 25 MG
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take one 25mg Carbidopa tablet 3 times a day for 10 days.
Study: NCT04752527
Drug: venetoclax combined with decitabine
Normalized name: decitabine, combinations
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: combination of venetoclax plus decitabine, and sorafenib for patients with high FLT3-ITD allelic ratio. (On day 1 of cycle 1, decitabine 20 mg/m2 will be given intravenously, and will continue for 5 days. Simultaneously the patient will start out with Venetoclax 100mg and progress to 400mg until the 28 day cycle is finished. For patients with high FLT3-ITD allelic ratio, sorafenib was administered at a dose of 400mg orally twice daily, on days 3 through 28.
Study: NCT04950426
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One administration of propranolol, once a week during six weeks. Reading by the participant of his/her traumatic story, 75 minutes (+/- 15 min) after propranolol intake.
Study: NCT05079841
Drug: Exogenous oxytocin intravenous infusion without nipple stimulation.
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to induce labor as current standard of care
Study: NCT06603285
Drug: Treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sc/iv continuously
Study: NCT04700072
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered via oral capsule at a specified dose on specified days
Study: NCT06603571
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered SC